The Role of 5α-Reductase Inhibitors (5-ARIs) in Prostate Cancer Chemoprevention
Prostate cancer, due to its high prevalence and long latency period, is an ideal candidate for prevention. Considerable effort has been placed on prevention strategies utilizing 5α-reductase inhibitors (5-ARIs). In this chapter, we will review the rationale and key studies examining the role of these drugs in primary and secondary prevention of prostate cancer.
KeywordsPlacebo Testosterone Androgen Finasteride Dihydrotestosterone
- 9.Wilt T, MacDonald R, Hagerty K, et al. 5-α reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008; 2: Art no.CD007091.Google Scholar
- 19.Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, REDEEM Study Group. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007;28(6):763–9.PubMedCrossRefGoogle Scholar
- 20.Fleshner N, Lucia MS, Melich K, Nandy I, Black L, Rittmaster R. Dutasteride reduces prostate cancer progression and cancer diagnosis on re-biopsy in the REDEEM active surveillance study. Abstract SUO. 2010.Google Scholar